Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
Haemonetics Corporation ( HAE ) Q2 2026 Earnings Call November 6, 2025 8:00 AM EST Company Participants Olga Guyette - Senior Director of Investor Relations Christopher Simon - CEO, President & Director James D'Arecca - CFO, Executive VP & Financial Officer Conference Call Participants Rohin Patel - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.
Haemonetics (HAE) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.12 per share a year ago.
Understanding Haemonetics (HAE) Reliance on International Revenue
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market share in the $19.68B HAE market if trials are successful.
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
Pharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formulations: an immediate-release capsule for acute attacks and a daily extended-release tablet. Phase 3 results for the immediate-release capsules (Rapide-3) are expected in Q4 2025.
